CompletedPhase 2

A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis

40 participantsStarted 2006-09

Plain-language summary

The purpose of the study is to test the efficacy of the combination treatment AllQbG10 in patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy in a double-blind, placebo-controlled setting

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Mild to moderate perennial allergic rhinoconjunctivitis due to hypersensitization towards house dust mite allergens Exclusion Criteria: * Clinically relevant other allergies (perennial or seasonal) that could potentially interfere with the patient's study treatment schedule or assessments * Use of any concomitant medication that could affect the patient's study treatment response or assessment results

What they're measuring

Conjunctival Provocation Test (CPT) With House Dust Mite Allergen Solutions. Change of Median Individual Allergen Tolerance Compared to Baseline (Factor of Increase in Allergen Concentration to Induce a Threshold CPT Score ≥ 2)

Timeframe: baseline versus 2 months after baseline

Trial details

NCT IDNCT00574704

SponsorCytos Biotechnology AG

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2008-03

Results submitted2013-02-14

View on ClinicalTrials.gov More Perennial Allergic Rhinoconjunctivitis trials